公开(公告)号：US20090324601A1

公开(公告)日：2009-12-31

申请号：US12376052

申请日：2007-08-02

申请人： David Charles Blakey ,  Susan Ann Cartlidge ,  Ian Foltz ,  Jaspal Singh Kang ,  Laura Taylor ,  Gadi Gazit-Bornstein ,  Naomi Laing

发明人： David Charles Blakey ,  Susan Ann Cartlidge ,  Ian Foltz ,  Jaspal Singh Kang ,  Laura Taylor ,  Gadi Gazit-Bornstein ,  Naomi Laing

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/11 ,  C12N15/00 ,  C12N5/06 ,  C12P21/02

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。

公开(公告)号：US07939637B2

公开(公告)日：2011-05-10

申请号：US11608705

申请日：2006-12-08

申请人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiaodong Yang ,  Susan Ann Cartlidge ,  David William Tonge

发明人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiaodong Yang ,  Susan Ann Cartlidge ,  David William Tonge

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/26

CPC分类号： C07K16/22 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63

摘要： Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

摘要翻译： 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。 特别地，公开了针对IGF-II的完全人单克隆抗体与IGF-I的交叉反应性。 还讨论了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是来自FR1至FR4或 CDR1到CDR3。

公开(公告)号：US08350011B2

公开(公告)日：2013-01-08

申请号：US12376196

申请日：2007-08-02

申请人： Susan Ann Cartlidge ,  Jianying Dong ,  Mark Hickinson ,  Ian Foltz ,  Jaspal Singh Kang

发明人： Susan Ann Cartlidge ,  Jianying Dong ,  Mark Hickinson ,  Ian Foltz ,  Jaspal Singh Kang

IPC分类号： C07K16/30 ,  A61K39/395

CPC分类号： C07K16/40 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

摘要翻译： 本发明涉及特异性结合ErbB2，优选人ErbB2的人抗体及其抗原结合部分的抗体。 在另一个实施方案中，抗体或其抗原结合部分抑制ErbB2。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗ErbB2抗体的分离的重链和轻链免疫球蛋白或其部分和编码这种免疫球蛋白的核酸分子。 本发明还涉及使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗ErbB2抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

公开(公告)号：US08410058B2

公开(公告)日：2013-04-02

申请号：US13078480

申请日：2011-04-01

申请人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiao-Dong Yang ,  Susan Ann Cartlidge ,  David William Tonge

发明人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiao-Dong Yang ,  Susan Ann Cartlidge ,  David William Tonge

IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/26

CPC分类号： C07K16/22 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63

摘要： Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

摘要翻译： 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。 特别地，公开了针对IGF-II的完全人单克隆抗体与IGF-I的交叉反应性。 还讨论了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是来自FR1至FR4或 CDR1到CDR3。

公开(公告)号：US20110200607A1

公开(公告)日：2011-08-18

申请号：US13078480

申请日：2011-04-01

申请人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiaodong Yang ,  Susan Ann Cartlidge ,  David William Tonge

发明人： Olivia Raeber ,  Gadi Gazit-Bornstein ,  Xiaodong Yang ,  Susan Ann Cartlidge ,  David William Tonge

IPC分类号： A61K39/395 ,  A61P35/00

CPC分类号： C07K16/22 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/303 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09 ,  C12N15/11 ,  C12N15/63

摘要： Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

摘要翻译： 描述了结合蛋白，例如针对IGF-II的抗体与IGF-1的交叉反应性和这种抗体的用途。 特别地，公开了针对IGF-II的完全人单克隆抗体与IGF-I的交叉反应性。 还讨论了编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是来自FR1至FR4或 CDR1到CDR3。